secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADMA BIOLOGICS, INC. (ADMA)
CIK:        0001368514
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001140361-26-007230
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADMA Biologics announces $125M accelerated share repurchase as part of $200M 2026 buyback plan
--------------------------------------------------------------------------------

- $125M ASR with JPMorgan; initial receipt of ~6.4M shares (~80% of expected) on March 3, 2026 at $15.57 close.
- Total 2026 share repurchase initiative target is ~$200M, funded via existing $225M revolving credit facility.
- Since program authorization in May 2025, ~$160M of common stock repurchased to date.
- CEO states stock is "meaningfully undervalued" relative to business strength and growth trajectory.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1368514/000114036126007230/0001140361-26-007230-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1368514/000114036126007230/ef20066774_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-007230

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer